Abstract Number: 0405 • ACR Convergence 2024
Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial
Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 inhibitor for treatment of rheumatoid arthritis and is being investigated in the open-label Phase 2 trial in adolescents…Abstract Number: 0526 • ACR Convergence 2024
Comparing Immunogenicity and Safety Following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Phase 3 Study
Background/Purpose: To assess immunogenicity and safety in patients with active rheumatoid arthritis (RA) transitioning from US-Rituximab (RP) or EU-Rituximab (RMP) to DRL_RI (proposed rituximab biosimilar),…Abstract Number: 0646 • ACR Convergence 2024
Chart Audit of over 1,000 SLE Patients Reveals Biologic Treatment Choice Driven by Disease Manifestations
Background/Purpose: To better understand how US rheumatologists utilize biologics in the management of SLE, especially among those with cutaneous manifestations. No medication is currently FDA-approved…Abstract Number: 0875 • ACR Convergence 2024
Targeted IL-15 Muteins Provide Selective Expansion of KIR+ CD8 Regulatory T Cells, with the Potential to Ameliorate Disease in Autoimmune Patients with Deficient CD8 Treg Populations
Background/Purpose: CD8 Treg, characterized in human peripheral blood mononuclear cells (PBMC) by expression of inhibitory killer immunoglobulin receptors (KIRs), regulate immune balance by eliminating self-reactive…Abstract Number: 1232 • ACR Convergence 2024
Patient Reported Impact of Psoriatic Arthritis and Desired Treatment Outcomes
Background/Purpose: People living with psoriatic arthritis often struggle with the physical and mental health toll. Understanding the holistic impact of psoriatic arthritis is crucial to…Abstract Number: 1468 • ACR Convergence 2024
Efficacy of bDMARDs in Early versus Established Disease in Axial Spondyloarthritis: A Meta-Analysis of Randomized Trials
Background/Purpose: The ASAS consensus definition of ‘early axial spondyloarthritis (axSpA)’ (axial symptoms ≤ 2 years) was expert-based given the scarcity of evidence1. We conducted a…Abstract Number: 1601 • ACR Convergence 2024
Changing Spectrum of Systemic Therapies for Eosinophilic Granulomatosis with Polyangiitis from 2006-2023
Background/Purpose: The emergence of biologic therapies targeting eosinophils via the IL-5 pathway provided new options for treatment in eosinophilic granulomatosis with polyangiitis (EGPA). There has…Abstract Number: 2032 • ACR Convergence 2024
A Systematic Review of Treatment Strategies in VEXAS Syndrome
Background/Purpose: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, first described in 2020, is an autoinflammatory condition characterized by somatic mutations in the UBA1 gene.…Abstract Number: 2344 • ACR Convergence 2024
Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-year Final Results of a Prospective Real-world Study
Background/Purpose: Real-world data on long-term use of secukinumab complements clinical trial findings by providing insights from diverse patients in routine clinical settings. SERENA (CAIN457A3403) was…Abstract Number: 2553 • ACR Convergence 2024
Predictors of Biologic and Targeted Synthetic DMARD Initiation for Rheumatoid Arthritis Across Underserved Patient Groups: Insights from a National Cohort Study
Background/Purpose: Quantifying healthcare inequality is essential to addressing the imbalance in outcomes attributable to age, gender, ethnicity and multimorbidity. In this study, we analysed differences…Abstract Number: 0141 • ACR Convergence 2024
The Effect of Systemic Immunosuppressive Therapies on Cardiovascular Risk in Psoriatic Arthritis Patients
Background/Purpose: Evidence demonstrates an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among psoriatic arthritis (PsA) patients. However, the relationship between immunosuppressive therapies and the development of ASCVD remains unclear.…Abstract Number: 0412 • ACR Convergence 2024
Impact of Approval of Biologic DMARDs on JIA Outcomes in a Single Center
Background/Purpose: In clinical trials, biologic disease-modifying antirheumatic drugs (bDMARDs) for juvenile idiopathic arthritis (JIA) have demonstrated good efficacy. However, less is known about the impact…Abstract Number: 0527 • ACR Convergence 2024
Risk Factors for Leukopenia in Asian Patients with Rheumatoid Arthritis Undergoing Tocilizumab
Background/Purpose: Leukopenia is an established adverse effect associated with tocilizumab(TCZ) therapy. Nevertheless, the extent of risk and its correlation with infection rates among Asian rheumatoid…Abstract Number: 0664 • ACR Convergence 2024
Impact of Hydroxychloroquine and Belimumab on Early Glucocorticoid Reduction in New-Onset Systemic Lupus Erythematosus: A Retrospective Analysis of Risk and Protective Factors
Background/Purpose: Glucocorticoid is a critical treatment option for systemic lupus erythematosus (SLE). However, long-term use is associated with numerous side effects and an increased risk…Abstract Number: 0944 • ACR Convergence 2024
Targeting Defective Macrophages to Restore Resolution of Inflammation in Rheumatoid Arthritis -Perspectives for an Autologous Secretome Therapy
Background/Purpose: Impaired macrophage efferocytosis, a key hallmark of failed inflammation resolution, is reported in many immune-mediated inflammatory diseases, including in Rheumatoid Arthritis (RA). Hence the…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 54
- Next Page »